MDXG
MiMedx Group, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-25
Figures on this page computed 2026-11-08 12:12 UTC
Last close
3.20USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-02-25
10.0xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001376339-26-000011
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-25
41.5%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001376339-26-000011
- Reported in
- USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-10-28
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-10-28
11.6%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001376339-26-000011
- Reported in
- USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
17.4%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001376339-26-000011
- Reported in
- USD
- 10-K for 2025, filed 2026-02-25
- 10-K for 2025, filed 2026-02-25
0.09Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001376339-26-000011
- Reported in
- USD
- 10-K for 2025, filed 2026-02-25
- 10-Q for 2025, filed 2026-10-28
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
- Growth11.0%56 of 100, above its sector
- Returns on capital41.5%92 of 100, above its sector
- Margins82.6%82 of 100, above its sector
- Price10.0x72 of 100, above its sector
- Safety0.0983 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 0 of 2- Profit on each unit of sales11.6%-8.5%Ahead
Higher is better here.
- Return on the capital it uses41.5%n/an/a
Higher is better here.
- Sales growth over five years11.0%-1.8%Ahead
Higher is better here.
- Debt against equity0.09n/an/a
Lower is better here.
- Gross margin82.6%n/an/a
Higher is better here.
- Price against earnings10.0xn/an/a
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Assembly Biosciences, Inc., MDXG is behind on 0 of 2 measures.
Against Assembly Biosciences, Inc., MDXG is behind on 0 of 2 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-25
Profit on each unit of sales11.6%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001376339-26-000011
- Reported in
- USD
Return on the capital it uses41.5%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001376339-26-000011
- Reported in
- USD
Sales growth over five years11.0%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001376339-26-000011
- Reported in
- USD
Debt against equity0.09
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001376339-26-000011
- Reported in
- USD
Gross margin82.6%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001376339-26-000011
- Reported in
- USD
Price against earnings10.0x
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001376339-26-000011
- Reported in
- USD